Anita Schmitt

5.9k total citations
142 papers, 3.5k citations indexed

About

Anita Schmitt is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Anita Schmitt has authored 142 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 63 papers in Immunology and 51 papers in Hematology. Recurrent topics in Anita Schmitt's work include CAR-T cell therapy research (65 papers), Immunotherapy and Immune Responses (40 papers) and Hematopoietic Stem Cell Transplantation (33 papers). Anita Schmitt is often cited by papers focused on CAR-T cell therapy research (65 papers), Immunotherapy and Immune Responses (40 papers) and Hematopoietic Stem Cell Transplantation (33 papers). Anita Schmitt collaborates with scholars based in Germany, China and United States. Anita Schmitt's co-authors include Michael Schmitt, Jochen Greiner, Hartmut Döhner, Mark Ringhoffer, Donald Bunjes, Markus Rojewski, Krzysztof Giannopoulos, Carsten Müller‐Tidow, Markus Wiesneth and Maria‐Luisa Schubert and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Anita Schmitt

137 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anita Schmitt Germany 33 1.7k 1.6k 1.0k 977 441 142 3.5k
Segundo González Spain 44 1.6k 0.9× 3.5k 2.2× 845 0.8× 648 0.7× 330 0.7× 109 5.2k
Gesine Bug Germany 35 1.3k 0.7× 1.2k 0.8× 1.6k 1.6× 2.3k 2.3× 253 0.6× 141 4.2k
Bart Vandekerckhove Belgium 37 1.0k 0.6× 2.0k 1.3× 1.8k 1.7× 427 0.4× 307 0.7× 132 4.4k
Aurore Saudemont United Kingdom 25 1.8k 1.0× 2.0k 1.3× 695 0.7× 654 0.7× 260 0.6× 55 3.0k
Michael Morgan Germany 32 1.5k 0.9× 1.0k 0.7× 2.5k 2.4× 2.2k 2.2× 712 1.6× 106 5.0k
Keyvan Keyvanfar United States 35 786 0.5× 1.6k 1.0× 1.3k 1.3× 1.5k 1.5× 521 1.2× 110 4.1k
Djordje Atanackovic Germany 43 2.1k 1.2× 2.1k 1.3× 1.6k 1.6× 1.2k 1.2× 242 0.5× 142 4.4k
Fawzia Louache France 37 827 0.5× 1.3k 0.8× 1.0k 1.0× 1.6k 1.7× 419 1.0× 92 3.8k
Edward D. Ball United States 31 1.2k 0.7× 1.3k 0.8× 1.2k 1.2× 1.1k 1.2× 378 0.9× 176 3.5k
Susan E. Prockop United States 26 1.0k 0.6× 1.0k 0.6× 581 0.6× 793 0.8× 366 0.8× 175 2.7k

Countries citing papers authored by Anita Schmitt

Since Specialization
Citations

This map shows the geographic impact of Anita Schmitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anita Schmitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anita Schmitt more than expected).

Fields of papers citing papers by Anita Schmitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anita Schmitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anita Schmitt. The network helps show where Anita Schmitt may publish in the future.

Co-authorship network of co-authors of Anita Schmitt

This figure shows the co-authorship network connecting the top 25 collaborators of Anita Schmitt. A scholar is included among the top collaborators of Anita Schmitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anita Schmitt. Anita Schmitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schubert, Maria‐Luisa, Peter Dreger, Anita Schmitt, et al.. (2024). Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study. Leukemia. 38(11). 2419–2428. 18 indexed citations
2.
Schairer, Rebekka, Hildegard Keppeler, Hannes Schmid, et al.. (2024). PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity. Journal for ImmunoTherapy of Cancer. 12(1). e007829–e007829. 7 indexed citations
3.
Chen, Qian, et al.. (2024). Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity. Blood. 144(Supplement 1). 3440–3440. 3 indexed citations
4.
Wang, Lei, Brigitte Neuber, Angela Hückelhoven‐Krauss, et al.. (2024). Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy. Blood Advances. 8(11). 2675–2690. 3 indexed citations
5.
John, Lukas, Sandra Sauer, Ute Hegenbart, et al.. (2023). Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy. 29(10). 609.e1–609.e6. 4 indexed citations
6.
Schubert, Maria‐Luisa, Carolina Berger, Alexander Kunz, et al.. (2022). Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients. International Journal of Oncology. 60(5). 9 indexed citations
7.
Bunse, Lukas, Claudia Sommerer, Chin Leng Tan, et al.. (2022). Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV. International Journal of Molecular Sciences. 23(3). 1029–1029. 2 indexed citations
8.
Gong, Wenjie, Lei Wang, Maria‐Luisa Schubert, et al.. (2022). HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. Biomedicines. 10(2). 373–373. 4 indexed citations
9.
Gong, Wenjie, Lei Wang, Sophia Stock, et al.. (2021). Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. Cells. 10(1). 152–152. 4 indexed citations
10.
11.
Yoo, Keun-Young, Sophia Stock, Lei Wang, et al.. (2020). Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients. International Journal of Cancer. 148(2). 419–428. 52 indexed citations
12.
Schubert, Maria‐Luisa, Alexander Kunz, Anita Schmitt, et al.. (2020). Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR. Cancers. 12(10). 2820–2820. 14 indexed citations
13.
Yoo, Keun-Young, Yibin Liu, Lei Wang, et al.. (2019). Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. International Journal of Molecular Sciences. 20(10). 2469–2469. 15 indexed citations
14.
Wang, Lei, Wenjie Gong, Sanmei Wang, et al.. (2019). Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. Cytotherapy. 21(5). 566–578. 17 indexed citations
15.
16.
Stock, Sophia, Jean‐Marc Hoffmann, Maria‐Luisa Schubert, et al.. (2018). Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells. Human Gene Therapy. 29(10). 1167–1182. 21 indexed citations
17.
Schmitt, Michael, Patrick Wuchter, Eike C. Buss, et al.. (2014). Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion. 55(2). 275–283. 33 indexed citations
18.
Schmitt, Michael, Xiangdong Xu, Inken Hilgendorf, et al.. (2013). Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. Bone Marrow Transplantation. 48(7). 922–925. 24 indexed citations
19.
Wang, Xinchao, Hua Pang, Xun Xu, et al.. (2012). Streptamer versus tetramer-based selection of functional cytomegalovirus-specific T cells. Journal of the Formosan Medical Association. 112(6). 338–345. 10 indexed citations
20.
Riedel, René, et al.. (1990). Gastrointestinal type 1 hypersensitivity to azathioprine. Journal of Molecular Medicine. 68(1). 50–52. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Segundo González Breakdown of academic impact, for papers by Gesine Bug Breakdown of academic impact, for papers by Bart Vandekerckhove Breakdown of academic impact, for papers by Aurore Saudemont Breakdown of academic impact, for papers by Michael Morgan Breakdown of academic impact, for papers by Keyvan Keyvanfar Breakdown of academic impact, for papers by Djordje Atanackovic Breakdown of academic impact, for papers by Fawzia Louache Breakdown of academic impact, for papers by Edward D. Ball Breakdown of academic impact, for papers by Susan E. Prockop
Rankless by CCL
2026